ORMP - ORAMED PHARMACEUTICALS INC.
IEX Last Trade
2.36
-0.010 -0.424%
Share volume: 3,078
Last Updated: Thu 26 Dec 2024 08:25:54 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$2.37
-0.01
-0.42%
Fundamental analysis
17%
Profitability
0%
Dept financing
12%
Liquidity
50%
Performance
27%
Performance
5 Days
0 0%
1 Month
0.42%
3 Months
-0.83%
6 Months
-7.39%
1 Year
10.19%
2 Year
-78.26%
Key data
Stock price
$2.36
DAY RANGE
$2.35 - $2.38
52 WEEK RANGE
$2.15 - $3.67
52 WEEK CHANGE
$1.71
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Nadav Kidron
Region: US
Website: oramed.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: oramed.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its flagship product is the ORMD-0801, an oral ingestible insulin capsule. It is also developing an oral glucagon-like peptide-1 capsule.
Recent news